Research programme: gene therapies - Audentes Therapeutics

Drug Profile

Research programme: gene therapies - Audentes Therapeutics

Alternative Names: AAV-CASQ2 gene therapy - Audentes; AAV-MTM1 (AT001); AT 132; AT 307; AT 982; AT-001 - Audentes/REGENXBIO; AT-002 - Audentes/REGENXBIO; AT-003 - Audentes/REGENXBIO; XLMTM gene therapy (AT001) - Audentes/Genethon

Latest Information Update: 29 May 2017

Price : $50

At a glance

  • Originator Audentes Therapeutics; Genethon
  • Class Gene therapies
  • Mechanism of Action Alpha glucosidase expression stimulants; Gene transference; Myotubularin expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Musculoskeletal disorders
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Glycogen storage disease type II; Musculoskeletal disorders; Ventricular tachycardia

Most Recent Events

  • 11 May 2017 US FDA approves IND application for AT 982 in Pompe Disease
  • 11 May 2017 Audentes completes enrolment in the INCEPTUS trial for Musculoskeletal disorders (X-linked myotubular myopathy) in USA, Canada, France, Germany and United Kingdom
  • 03 Apr 2017 USFDA approves IND application for AT 132 in X-linked myotubular myopathy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top